

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

Art Unit: 1642

Hohneker, John Arthur et al.

Examiner: Fetterolf, Brandon J

INTERNATIONAL APPLICATION NO: PCT/EP03/05988

FILED: June 06, 2003

U.S. APPLICATION NO: 10/517074

35 USC §371 DATE: April 19, 2005

FOR: Combinations Comprising Epothilones and Pharmaceutical Uses
Thereof

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
(862) 778-7824

Date: 6/3/10

Respectfully submitted,



George Dohmann
Attorney for Applicant
Reg. No. 33,593